BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15245441)

  • 1. Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells.
    Kunikata N; Sano K; Honda M; Ishii K; Matsunaga J; Okuyama R; Takahashi K; Watanabe H; Tamura G; Tagami H; Terui T
    J Invest Dermatol; 2004 Aug; 123(2):395-402. PubMed ID: 15245441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
    Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
    Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
    Najar HM; Dutz JP
    J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
    Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
    Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.
    Heckelsmiller K; Rall K; Beck S; Schlamp A; Seiderer J; Jahrsdörfer B; Krug A; Rothenfusser S; Endres S; Hartmann G
    J Immunol; 2002 Oct; 169(7):3892-9. PubMed ID: 12244187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.
    Kawarada Y; Ganss R; Garbi N; Sacher T; Arnold B; Hämmerling GJ
    J Immunol; 2001 Nov; 167(9):5247-53. PubMed ID: 11673539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response.
    Sfondrini L; Besusso D; Bronte V; Macino B; Rossini A; Colombo MP; Ménard S; Balsari A
    Cancer Immunol Immunother; 2004 Aug; 53(8):697-704. PubMed ID: 15034674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
    Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
    Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
    Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.
    Sfondrini L; Sommariva M; Tortoreto M; Meini A; Piconese S; Calvaruso M; Van Rooijen N; Bonecchi R; Zaffaroni N; Colombo MP; Tagliabue E; Balsari A
    Int J Cancer; 2013 Jul; 133(2):383-93. PubMed ID: 23319306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency.
    Keyser J; Schultz J; Ladell K; Elzaouk L; Heinzerling L; Pavlovic J; Moelling K
    Exp Dermatol; 2004 Jun; 13(6):380-90. PubMed ID: 15186325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo.
    Oh SM; Oh K; Lee DS
    J Korean Med Sci; 2011 Oct; 26(10):1270-6. PubMed ID: 22022177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
    Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
    Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel Ag-specific immunotherapy using CpG oligodeoxynucleotides in a new, unique mouse cutaneous eosinophilic inflammation model.
    Kootiratrakarn T; Fujimura T; Sano K; Okuyama R; Aiba S; Tagami H; Terui T
    Eur J Immunol; 2005 Nov; 35(11):3277-86. PubMed ID: 16245360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice.
    Akiba H; Satoh M; Iwatsuki K; Kaiserlian D; Nicolas JF; Kaneko F
    J Invest Dermatol; 2004 Sep; 123(3):488-93. PubMed ID: 15304088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
    Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
    PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.